Gobroad Research Center

Gobroad Healthcare Group is a leading clinical research-driven healthcare organization in China, specializing in hematology, oncology, and cell therapy. Founded in 2017 and backed by Hillhouse Capital, the group operates a network of specialized hospitals and research centers across Beijing, Shanghai, and Guangdong. The organization is renowned for its expertise in hematopoietic stem cell transplantation and serves as a premier site for early-phase clinical trials, particularly for innovative CAR-T cell therapies. By integrating high-end diagnostics, clinical care, and translational research, Gobroad accelerates the development of novel treatments for complex blood cancers. The group maintains strategic collaborations with top-tier academic institutions and international medical centers to advance precision medicine.